R

Roche

Global pharmaceuticals and diagnostics company

Full-Stack AI Engineer / Data Scientist - Agentic Systems

Full-TimeDeadline 10/23/26
No salary listed
Senior
Bachelor's, Master's, PhD
Hyderabad, Telangana, India
RemoteOccasional work hours must span the Central European Time zone.
Software EngineeringAI Application Engineering, Full-Stack Engineering

About the job

Requirements
  • At least 7 years of experience in artificial intelligence/machine learning engineering and data science, including generative artificial intelligence, agents, and classical machine learning.
  • At least 3 years of hands-on experience with generative large language models and agents.
  • Proven experience managing the end-to-end machine learning operations lifecycle and deploying models at scale.
  • Proven experience leveraging artificial intelligence coding agents within an agentic software development lifecycle.
  • Advanced production-grade proficiency in Python.
  • Deep expertise with LangChain or similar large language model orchestration frameworks, agentic system design, and state machine logic.
  • Practical experience designing cloud solutions on Amazon Web Services and using generative artificial intelligence services such as Amazon Bedrock and SageMaker.
  • Strong knowledge of vector databases such as Amazon Web Services OpenSearch, graph databases, Snowflake, SQL, NoSQL, and data lakes.
  • Expertise in application programming interface design, continuous integration and continuous delivery, Docker, infrastructure as code, and rigorous automated testing.
  • Strong background in statistics, data manipulation, synthetic data generation, and feature engineering.
  • Ability to define architectural patterns and step into a Tech Lead role when necessary.
  • Ability to work closely with enterprise stakeholders to consult on technological approaches to business problems.
  • Strong understanding of biases, fairness, hallucination mitigation, and responsible artificial intelligence deployment.
  • Bachelor of Science, Bachelor of Engineering, Master of Science, Master of Engineering, Doctor of Philosophy, or equivalent in Computer Science, Physics, Statistics, Mathematics, or a related field.
  • Ability to communicate in English at C1 or higher level.
  • Readiness to span work times across the Central European Time Zone on occasion when necessary.
Responsibilities
  • Design and build advanced agentic artificial intelligence systems, state machines, and search-based conversational systems for complex business problems.
  • Develop workflows using large foundational multimodal models to process and reason across text, audio, and video.
  • Implement Model Context Protocol servers and clients to standardize context exchange between agents, data sources, and external tools.
  • Collaborate with AI Architects, Product Owners, and developers to integrate AI capabilities into scalable, fair, ethical end-user applications.
  • Use AI coding agents such as Claude Code to accelerate full-stack development across frontend, backend, and infrastructure tasks.
  • Own features end to end by writing production-ready Python and occasionally TypeScript code with comprehensive testing and documentation.
  • Manage the DevOps and machine learning operations lifecycle, containerize applications with Docker, configure continuous integration and continuous delivery pipelines, and architect reliable cloud-native solutions on Amazon Web Services and multicloud environments.
  • Perform exploratory data analysis to understand datasets, uncover patterns, detect biases, and identify data-quality issues.
  • Use statistical and visualization techniques to inform feature engineering, model selection, and optimization of foundation-model applications.
  • Design data pipelines to curate, preprocess, and structure diverse datasets to improve large language model effectiveness and reduce bias.
  • Design, customize, optimize, and fine-tune large language model-based and traditional artificial intelligence algorithms for use cases including text generation, summarization, AI agents, and sequence modeling.
  • Lead prompt-engineering strategies using zero-shot, few-shot, and other paradigms to optimize model outputs.
  • Implement classification, clustering, and regression models when they are more efficient, interpretable, or cost-effective than large language models.
  • Optimize model inference speed, reduce latency through cold-start reduction and caching strategies, and manage resource usage across cloud architectures.
  • Conduct experimentation and A/B testing and implement automatic metric pipelines using measures such as BLEU, ROUGE, retrieval accuracy, and human-rating frameworks.
  • Implement real-time algorithm monitoring and observability practices for pipeline visibility, drift detection, and anomaly identification using telemetry tools.
  • Translate complex technical results into clear, actionable insights for stakeholders and support data-driven decision-making.
Desired Qualifications
  • Additional proficiency in TypeScript is considered an advantage.
  • Familiarity with multicloud platforms is a plus.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.